Published in Blood on March 15, 2007
Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24
Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev (2010) 1.97
The blood-brain barrier, chemokines and multiple sclerosis. Biochim Biophys Acta (2010) 1.40
Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J Exp Med (2008) 1.34
Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation. J Leukoc Biol (2008) 1.25
The X-ray crystal structure of human aminopeptidase N reveals a novel dimer and the basis for peptide processing. J Biol Chem (2012) 1.12
The chemokine receptor CXCR7 functions to regulate cardiac valve remodeling. Dev Dyn (2011) 1.03
Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood (2010) 1.02
Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment. Proc Natl Acad Sci U S A (2012) 0.99
Posttranslational modification of the NH2-terminal region of CXCL5 by proteases or peptidylarginine Deiminases (PAD) differently affects its biological activity. J Biol Chem (2010) 0.98
T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov (2014) 0.93
Ectoenzymes in leukocyte migration and their therapeutic potential. Semin Immunopathol (2014) 0.90
Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes. Immunology (2011) 0.90
Discrimination of agonist and antagonist forms of CXCL10 in biological samples. Clin Exp Immunol (2012) 0.85
Convolution of chemoattractant secretion rate, source density, and receptor desensitization direct diverse migration patterns in leukocytes. Integr Biol (Camb) (2013) 0.83
Cysteine Cathepsins Activate ELR Chemokines and Inactivate Non-ELR Chemokines. J Biol Chem (2015) 0.82
Multiple roles for chemokines in the pathogenesis of SIV infection. Curr HIV Res (2009) 0.80
HIV persistence: chemokines and their signalling pathways. Cytokine Growth Factor Rev (2012) 0.80
Biological activity of CXCL8 forms generated by alternative cleavage of the signal peptide or by aminopeptidase-mediated truncation. PLoS One (2011) 0.79
Regulation of Chemokine Activity - A Focus on the Role of Dipeptidyl Peptidase IV/CD26. Front Immunol (2016) 0.79
Expression and function of aminopeptidase N/CD13 produced by fibroblast-like synoviocytes in rheumatoid arthritis: role of CD13 in chemotaxis of cytokine-activated T cells independent of enzymatic activity. Arthritis Rheumatol (2015) 0.77
CD14 in the TLRs signaling pathway is associated with the resistance to E. coli F18 in Chinese domestic weaned piglets. Sci Rep (2016) 0.76
Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post-translational modification: prospective placebo-controlled clinical studies. EMBO Mol Med (2016) 0.75
Natural nitration of CXCL12 reduces its signaling capacity and chemotactic activity in vitro and abrogates intra-articular lymphocyte recruitment in vivo. Oncotarget (2016) 0.75
Onco-GPCR signaling and dysregulated expression of microRNAs in human cancer. J Hum Genet (2016) 0.75
Glycosaminoglycans Regulate CXCR3 Ligands at Distinct Levels: Protection against Processing by Dipeptidyl Peptidase IV/CD26 and Interference with Receptor Signaling. Int J Mol Sci (2017) 0.75
Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem (2003) 4.79
The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev (2003) 3.96
Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med (2003) 3.91
The role of CXC chemokines and their receptors in cancer. Cancer Lett (2008) 3.84
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev (2009) 3.65
Macrophage inflammatory protein-1. Cytokine Growth Factor Rev (2002) 2.93
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62
Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev (2006) 2.57
Chemerin--a new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Commun (2007) 2.00
The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood (2007) 1.99
Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem (2003) 1.93
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology (2005) 1.88
Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res (2002) 1.86
Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol (2005) 1.80
Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and interleukin-8/CXCL8. J Biol Chem (2006) 1.79
Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J Immunol (2005) 1.70
Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol (2004) 1.69
The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. J Biol Chem (2003) 1.67
Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med (2008) 1.67
Differential regulation of chemokine production by Fcgamma receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2). J Leukoc Biol (2006) 1.63
Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev (2005) 1.59
Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) (2001) 1.57
Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. J Biol Chem (2009) 1.55
Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem (2002) 1.55
Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J Exp Med (2005) 1.54
Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw (2006) 1.52
Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines. Eur J Immunol (2014) 1.52
Predominance of aqueous Tl(I) species in the river system downstream from the abandoned Carnoulès mine (Southern France). Environ Sci Technol (2011) 1.47
Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol Pharmacol (2006) 1.47
The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem (2002) 1.46
Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model. J Immunol (2009) 1.45
Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J Biol Chem (2007) 1.45
Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. J Biol Chem (2002) 1.44
Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology (2005) 1.41
Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell (2002) 1.39
Allosteric properties of G protein-coupled receptor oligomers. Pharmacol Ther (2007) 1.39
Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J Exp Med (2008) 1.34
Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem Biophys Res Commun (2003) 1.33
Synergy in cytokine and chemokine networks amplifies the inflammatory response. Cytokine Growth Factor Rev (2005) 1.30
G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates. J Virol (2003) 1.30
Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon-beta. J Neuropathol Exp Neurol (2008) 1.29
Synergy between coproduced CC and CXC chemokines in monocyte chemotaxis through receptor-mediated events. Mol Pharmacol (2008) 1.29
Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev (2011) 1.28
Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp Cell Res (2010) 1.27
GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. Exp Cell Res (2005) 1.24
Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin Immunol (2006) 1.24
Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. J Med Chem (2007) 1.23
Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am J Pathol (2010) 1.21
The expression and role of CXC chemokines in colorectal cancer. Cytokine Growth Factor Rev (2011) 1.21
Regulation of chemokine activity by posttranslational modification. Pharmacol Ther (2008) 1.21
Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis. Clin Immunol (2011) 1.20
CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-gamma-induced chemokines. Eur J Immunol (2008) 1.20
Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J Immunol (2004) 1.19
RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci U S A (2006) 1.19
Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev (2005) 1.19
Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration. J Leukoc Biol (2004) 1.19
The role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancer. Biochim Biophys Acta (2011) 1.18
Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res (2004) 1.18
Citrullination of CXCL12 differentially reduces CXCR4 and CXCR7 binding with loss of inflammatory and anti-HIV-1 activity via CXCR4. J Immunol (2009) 1.15
Chemokines and gelatinases in the aqueous humor of patients with active uveitis. Am J Ophthalmol (2004) 1.15
Unique regulation of CCL18 production by maturing dendritic cells. J Immunol (2003) 1.14
Identification and characterization of an endogenous chemotactic ligand specific for FPRL2. J Exp Med (2004) 1.14
Immunopathology and dexamethasone therapy in a new model for malaria-associated acute respiratory distress syndrome. Am J Respir Crit Care Med (2010) 1.14